The use of psychotropic drugs in irritable bowel syndrome
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Irritable bowel syndrome (IBS), the most common functional gastrointestinal disorder, is manifested by chronic abdominal pain associated with irregular bowel movements. Although not life threatening, IBS is associated with impaired quality of life that ranges from mild to severe. AREAS COVERED: The pathogenesis of IBS is not completely understood, but involves dysfunction of the "brain-gut axis" including peripheral visceral hypersensitivity and central maladaptive processing of visceral pain input. Stress and concomitant psychopathologies such as somatization, anxiety and depression are thought to play a major role in the development, clinical course and response to treatment. Psychopharmacological agents such as selective serotonin/serotonin-norepinephrine receptor antagonists, tricyclic antidepressants as well as other agents are commonly used in treating moderate to severe IBS. This review will provide the pathophysiological rationale for the use of psychopharmacological agents in IBS, review the main classes of drugs and evidence for their use in IBS and offer a practical approach to the use of these drugs. EXPERT OPINION: Psychotropic drugs can play a pivotal role in the treatment of IBS patients, so doctors should be familiar with their use. Further research with these drugs is needed to solidify our current knowledge and increase our therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
Self-citationGut feelings: the emerging biology of gut-brain communication
Mayer, E. A. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3071 · Cited by 1,726 · cited 1×
“As a result, the mechanisms by which central mechanisms modulate hypersensitivity have drawn increased research interest [7,13].”
BackgroundAGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 1×
“Buspirone is a non-benzodiazepine, anti-anxiety agent that is used in psychiatry to augment the effect of antidepressants [73].”
BackgroundThe impact of irritable bowel syndrome on health-related quality of life
Gralnek, I. M., Hays, R. D., Kilbourne, A., Naliboff, B., & Mayer, E. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.16484 · Cited by 781 · cited 1×
“Although not a life threatening condition, IBS causes a considerable degree of impairment in patients’ quality of life [3] and, because of its chronic nature, can lead to many years of suffering.”
BackgroundDrossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., Emmott, S., Proffitt, V., Akman, D., Frusciante, K., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00669-3 · Cited by 614 · cited 1×
“evaluated the efficacy of a 12-week treatment with desipramine in 431 women with moderate to severe IBS [43].”
MethodSelf-citationFord, A. C., Talley, N. J., Schoenfeld, P. S., Quigley, E. M. M., & Moayyedi, P. (2009) · Gut · doi:10.1136/gut.2008.163162 · Cited by 582
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome
Creed, F., Fernandes, L., Guthrie, E., Palmer, S., Ratcliffe, J., Read, N., Rigby, C., Thompson, D., & Tomenson, B. (2003) · Gastroenterology · doi:10.1053/gast.2003.50055 · Cited by 443 · cited 1×
“Three studies evaluated the use of paroxetine for 12 weeks vs placebo [51-53].”
BackgroundBulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome
Ruepert, L., Quartero, A. O., de Wit, N. J., van der Heijden, G. J., Rubin, G., & Muris, J. W. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003460.pub3 · Cited by 389 · cited 1×
“There are numerous published meta-analyses and systematic reviews that evaluated the efficacy of antidepressants and TCAs in IBS, the most recent of which is a Cochrane review from 2011 [40].”
BackgroundGaylord, S. A., Palsson, O. S., Garland, E. L., Faurot, K. R., Coble, R. S., Mann, D. J., Frey, W., Leniek, K., & Whitehead, W. E. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.184 · Cited by 281
Altered Rectal Perception in Irritable Bowel Syndrome Is Associated With Symptom Severity
Posserud, I., Syrous, A., Lindström, L., Tack, J., Abrahamsson, H., & Simrén, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.07.024 · Cited by 248 · cited 1×
“However, studies conducted over recent years have demonstrated repeatedly that only about 50 -- 60% of IBS patients manifest visceral hypersensitivity [10,11].”
BackgroundThe immune system in irritable bowel syndrome
Barbara, G., Cremon, C., Carini, G., Bellacosa, L., Zecchi, L., Giorgio, R. D., Corinaldesi, R., & Stanghellini, V. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.4.349 · Cited by 211 · cited 1×
“Psychological stress has been shown to induce visceral hypersensitivity in animal models by promoting an immune-mediated inflammatory response predominantly through mast cells [23,24].”
BackgroundLackner, J. M., Jaccard, J., Krasner, S. S., Katz, L. A., Gudleski, G. D., & Holroyd, K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.004 · Cited by 176 · cited 1×
“While non-pharmacological treatment modalities such as cognitive behavioral therapy, psychotherapy, hypnosis, relaxation techniques and meditation have been tested and found to be helpful in IBS [28-33], this paper will focus on centrally acting drug treatment in IBS.”
BackgroundLindfors, P., Unge, P., Arvidsson, P., Nyhlin, H., Björnsson, E., Abrahamsson, H., & Simrén, M. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.340 · Cited by 138 · cited 1×
“While non-pharmacological treatment modalities such as cognitive behavioral therapy, psychotherapy, hypnosis, relaxation techniques and meditation have been tested and found to be helpful in IBS [28-33], this paper will focus on centrally acting drug treatment in IBS.”
BackgroundChang, L., Berman, S., Mayer, E. A., Suyenobu, B., Derbyshire, S., Naliboff, B., Vogt, B., FitzGerald, L., & Mandelkern, M. A. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07478.x · Cited by 122 · cited 1×
“This same phenomenon is found in other chronic pain syndromes such as fibromyalgia [14-16].”
BackgroundA controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome
Blanchard, E. B., Lackner, J. M., Sanders, K., Krasner, S., Keefer, L., Payne, A., Gudleski, G. D., Katz, L., Rowell, D., Sykes, M., et al. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2006.07.003 · Cited by 121 · cited 1×
“While non-pharmacological treatment modalities such as cognitive behavioral therapy, psychotherapy, hypnosis, relaxation techniques and meditation have been tested and found to be helpful in IBS [28-33], this paper will focus on centrally acting drug treatment in IBS.”
BackgroundKennedy, T., Chalder, T., McCrone, P., Darnley, S., Knapp, M., Jones, R., & Wessely, S. (2006) · Health Technology Assessment · doi:10.3310/hta10190 · Cited by 92 · cited 1×
“While non-pharmacological treatment modalities such as cognitive behavioral therapy, psychotherapy, hypnosis, relaxation techniques and meditation have been tested and found to be helpful in IBS [28-33], this paper will focus on centrally acting drug treatment in IBS.”
Background
Cited by
Irritable Bowel Syndrome: A Clinical Review
Chey, W. D., Kurlander, J., & Eswaran, S. (2015) · JAMA · doi:10.1001/jama.2015.0954 · Cited by 1,081
Van Oudenhove, L., Levy, R. L., Crowell, M. D., Drossman, D. A., Halpert, A. D., Keefer, L., Lackner, J. M., Murphy, T. B., & Naliboff, B. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.027 · Cited by 512
Self-citationImpact of psychological stress on irritable bowel syndrome
Qin, H.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14126 · Cited by 398
Leigh, H. (2015) · Handbook of Consultation-Liaison Psychiatry · doi:10.1007/978-3-319-11005-9_14 · Cited by 309
Psychological comorbidity in gastrointestinal diseases: Update on the brain-gut-microbiome axis
Person, H., & Keefer, L. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110209 · Cited by 158
Metadata
- Authors
- Dekel, R., Drossman, D. A., & Sperber, A. D.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2013-01-15
- Volume
- 22
- Issue
- 3
- Pages
- 329-339
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2110111660
- Cited by
- 78
- References
- 17
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.